Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HCG Clear all

Conditions: Hypogonadotropic Hypogonadism
Interventions: Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Embryo Transfer, Intrauterine Insemination (IUI)
Interventions: Semi-quantitative urine pregnancy test; Device
Lead sponsor: Gynuity Health Projects; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Infertility
Interventions: HCG is introduced; Drug
Lead sponsor: Servy Massey Fertility Insititute; Other
Eligibility: 21 Years to 47 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Graft vs Host Disease
Interventions: Pregnyl®; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 76 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Trisomy 21
Interventions: Not listed
Lead sponsor: Roche Sequencing Solutions; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 18,955 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Tucson, Arizona • Oakland, California • Palo Alto, California + 20 more

Conditions: Graft Versus Host Disease
Interventions: uhCG/EGF; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Medical Abortion
Interventions: Self-assessment: MLPT, Self-assessment: LSPT; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer
Interventions: hCG; Drug
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Preterm Delivery
Interventions: Not listed
Lead sponsor: Esoterix Genetic Laboratories, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Westborough, Massachusetts • Santa Fe, New Mexico

Conditions: Stroke
Interventions: NTx™-265: rhCG, then rEPO, Saline Placebo; Drug
Lead sponsor: Stem Cell Therapeutics Corp.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Newport Beach, California • Orange, California

Conditions: Stroke
Interventions: human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Saline Placebo; Drug
Lead sponsor: Stem Cell Therapeutics Corp.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orange, California

Conditions: Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
Interventions: DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF; Drug · Combination Product
Lead sponsor: Prism Health North Texas; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pregnancy
Interventions: Clearblue Pregnancy Test; Diagnostic Test
Lead sponsor: SPD Development Company Limited; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pregnancy
Interventions: Test Device-Strip Format, Test Device-Cassette Format, Predicate Device; Device
Lead sponsor: Guangzhou Wondfo Biotech Co., Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Garden Grove, California • Huntington Park, California • Los Angeles, California + 2 more

Conditions: Acute-graft-versus-host Disease
Interventions: Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: SPD Development Company Limited; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Edina, Minnesota + 2 more

Conditions: Pregnancy
Interventions: Clearblue pregnancy test; Diagnostic Test
Lead sponsor: SPD Development Company Limited; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 204 participants
Timeline: 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pregnancy
Interventions: Clara Pregnancy Test, Professional Marketed Pregnancy Test; Device
Lead sponsor: Conceptra Biosciences, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Abortion in First Trimester
Interventions: Choice of follow-up option, Multi-level pregnancy test; Other · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Undesired Pregnancy
Interventions: Not listed
Lead sponsor: Planned Parenthood League of Massachusetts; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Hyperstimulation Syndrome
Interventions: hCG; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Pregnancy Related, Abortion
Interventions: Not listed
Lead sponsor: Simple HealthKit; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Bladder Cancer
Interventions: CDX-1307 Vaccine Regimen, Chemotherapy; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 17
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more

Conditions: Infertility, Female
Interventions: Low dose hCG; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 46 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Search by objective public record fields.

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Semi-quantitative Pregnancy Test to Monitor hCG Levels After Assisted Fertility Treatment

Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

Non-invasive Chromosomal Examination of Trisomy Study

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Medical Abortion Self-Confirmation (MASC)

Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women

Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Doravirine and Weight Gain in Antiretroviral Naive

Clearblue Pregnancy Test Lay User Usage Study

Clinical Investigation for the Preview® hCG Urine/Serum Combo Pregnancy Test

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Performance Evaluation Study for Clearblue Pregnancy Test

Clearblue Pregnancy Test - Lay User Study

Predicate and Lay User-HCP Comparison Study of a Multi-Level Urine hCG Pregnancy Test

Choice of Modality of Follow up for Medication Abortion

Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion

Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS

Determining Beta-hCG Levels in Patients Through Alternative Sample Types

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes